ONC · BeOne Medicines Ltd.

BeOne Medicines delivered a strong first quarter in 2026, with total revenue climbing 35% year-over-year to $1.5 billion, primarily fueled by the robust performance of its flagship hematology franchise. BRUKINSA (zanubrutinib) solidified its market position as the foundational BTK inhibitor, generating $1.1 billion in global sales, a 38% increase driven by U.S. growth and global expansion. TEVIMBRA (tislelizumab) also contributed to the top-line growth with a 20% sales increase to $206 million. The company achieved significant operating leverage, with GAAP gross margin expanding to 89% from 85% in the prior year, attributed to a favorable sales mix and manufacturing productivity improvements. Consequently, GAAP net income surged to $227 million, compared to $1.3 million in the prior-year period. Management highlighted the competitive advantages of BRUKINSA and the potential of the sonrotoclax and BRUKINSA combination in first-line CLL. Looking forward, BeOne raised its full-year 2026 revenue guidance to a range of $6.3 to $6.5 billion and increased its GAAP operating income expectations to $750 to $850 million, signaling confidence in sustained commercial execution and operational efficiency.